PanGen Biotech Inc. (KOSDAQ:222110)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,010.00
-190.00 (-3.06%)
At close: Apr 28, 2026
5.81%
Market Cap 81.10B
Revenue (ttm) 13.42B
Net Income (ttm) 2.05B
Shares Out 13.49M
EPS (ttm) 146.00
PE Ratio 41.16
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 211,657
Average Volume 354,318
Open 6,170.00
Previous Close 6,200.00
Day's Range 5,760.00 - 6,170.00
52-Week Range 4,505.00 - 8,510.00
Beta -0.17
RSI 53.08
Earnings Date n/a

About PanGen Biotech

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 222110
Full Company Profile

Financial Performance

In 2025, PanGen Biotech's revenue was 13.42 billion, a decrease of -8.56% compared to the previous year's 14.67 billion. Earnings were 2.05 billion, an increase of 117.30%.

Financial Statements

News

There is no news available yet.